About Perceive Bio
Perceive Bio is a company based in San Francisco (United States) founded in 2021 by Anne Rubin. Perceive Bio has raised $78 million across 1 funding round from investors including Johnson & Johnson Innovation, Deerfield and Retinal Degeneration Fund. Perceive Bio offers products and services including Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies. Perceive Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter San Francisco, United States
- Founders Anne Rubin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Perceive Biotherapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78 M (USD)
in 1 rounds
-
Latest Funding Round
$78 M (USD), Series B
Jan 05, 2023
-
Investors
Johnson & Johnson Innovation
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Perceive Bio
Perceive Bio offers a comprehensive portfolio of products and services, including Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies.
Develops treatments for dry AMD and retinal neuroprotection via biological innovations
Targets dry age-related macular degeneration to prevent vision loss
Focuses on protecting retinal cells from degeneration through research
People of Perceive Bio
Unlock access to complete
Funding Insights of Perceive Bio
Perceive Bio has successfully raised a total of $78M through 1 strategic funding round. The most recent funding activity was a Series B round of $78 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Perceive Bio
Perceive Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson Innovation, Deerfield and Retinal Degeneration Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Investments are focused on retinal degeneration therapeutic solutions.
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for Perceive Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Perceive Bio
Investment portfolio details for Perceive Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Perceive Bio
Detailed financials for Perceive Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Perceive Bio Comparisons
Peer comparison for Perceive Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Perceive Bio
Perceive Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Perceive Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Perceive Bio
Complete news archive for Perceive Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perceive Bio
Perceive Bio was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Perceive Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
K Angela Macfarlane is the current CEO of Perceive Bio.
Perceive Bio is a funded company, having raised a total of $78M across 1 funding round to date.
Perceive Bio was founded in 2021 and is headquartered in San Francisco, United States. Therapeutics are developed by the company to address diabetes and various eye diseases. A pipeline of drugs is being advanced for conditions including retinal degeneration, dry age-related macular degeneration, neuroprotection, and central nervous system disorders. Operations focus on biotechnology research and drug development in the healthcare sector.
Perceive Bio's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Perceive Bio offers Pipeline Assets, Therapeutics for Dry AMD, and Neuroprotection Therapies.
Perceive Bio has 5 investors. Key investors include Johnson & Johnson Innovation, Deerfield, Retinal Degeneration Fund, Catalio Capital Management, and Braidwell.